Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
Vergote I, Pérez-Fidalgo JA, Hamilton EP, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller DS, Klat J, Martínez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Høgdall E, Fariñas-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V; ENGOT-EN5/GOG-3055/SIENDO Investigators. Vergote I, et al. Among authors: valabrega g. J Clin Oncol. 2023 Dec 10;41(35):5400-5410. doi: 10.1200/JCO.22.02906. Epub 2023 Sep 5. J Clin Oncol. 2023. PMID: 37669480 Clinical Trial.
Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer.
Rossi V, Sarotto I, Maggiorotto F, Berchialla P, Kubatzki F, Tomasi N, Redana S, Martinello R, Valabrega G, Aglietta M, Ponzone R, Montemurro F. Rossi V, et al. Among authors: valabrega g. Oncologist. 2012;17(11):1418-25. doi: 10.1634/theoncologist.2012-0194. Epub 2012 Sep 4. Oncologist. 2012. PMID: 22951668 Free PMC article.
PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma.
D'Ambrosio C, Erriquez J, Arigoni M, Capellero S, Mittica G, Ghisoni E, Borella F, Katsaros D, Privitera S, Ribotta M, Maldi E, Di Nardo G, Berrino E, Venesio T, Ponzone R, Vaira M, Hall D, Jimenez-Linan M, Paterson AL, Calogero RA, Brenton JD, Valabrega G, Di Renzo MF, Olivero M. D'Ambrosio C, et al. Among authors: valabrega g. Cells. 2020 Feb 14;9(2):442. doi: 10.3390/cells9020442. Cells. 2020. PMID: 32075097 Free PMC article.
Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial.
Montemurro F, Redana S, Valabrega G, Martinello R, Aglietta M, Palmiero R. Montemurro F, et al. Among authors: valabrega g. J Clin Oncol. 2008 Apr 20;26(12):2052-3; author reply 2053-4. doi: 10.1200/JCO.2007.15.5044. J Clin Oncol. 2008. PMID: 18421060 No abstract available.
Trastuzumab treatment in breast cancer.
Montemurro F, Valabrega G, Aglietta M. Montemurro F, et al. Among authors: valabrega g. N Engl J Med. 2006 May 18;354(20):2186; author reply 2186. doi: 10.1056/NEJMc060852. N Engl J Med. 2006. PMID: 16707759 No abstract available.
Modeling ErbB2-p130Cas interaction to design new potential anticancer agents.
Costamagna A, Rossi Sebastiano M, Natalini D, Simoni M, Valabrega G, Defilippi P, Visentin S, Ermondi G, Turco E, Caron G, Cabodi S. Costamagna A, et al. Among authors: valabrega g. Sci Rep. 2019 Feb 28;9(1):3089. doi: 10.1038/s41598-019-39510-w. Sci Rep. 2019. PMID: 30816273 Free PMC article.
114 results